LONDON - Scancell Holdings plc, a company specializing in the development of innovative cancer immunotherapies, has announced its intention to raise at least £8.5 million. The funds are to be raised through a combination of a placing of new ordinary shares and a subscription by a company director, with an additional retail offering expected to contribute further capital.
The placing will involve issuing new ordinary shares at 10.5 pence each to both new and existing institutional investors, as well as certain other investors, in an effort to raise the minimum target amount. A company director is also set to subscribe to new ordinary shares amounting to approximately £20,000 at the same issue price.
In addition to the placing and subscription, Scancell is also planning a retail offer to its existing UK shareholders. This offer aims to raise up to an additional £1 million through the Winterflood Retail Access Platform. The retail offer is scheduled to open today and will accept applications until the morning of December 9, 2024, subject to potential changes agreed upon by the company and its advisors.
The capital raised is expected to fund several key clinical data outcomes and extend the company's cash runway into the second half of 2026. This includes data on SCIB1, the company's lead cancer vaccine, and iSCIB1+, a next-generation treatment. The funds will also support the company's ongoing recruitment, partnering, and out-licensing discussions, as well as provide additional operational working capital.
The raise is being facilitated through an accelerated bookbuilding process, which commenced immediately following the announcement. The placing is not underwritten and is not open to the public. Admission of the new shares to trading on AIM is anticipated around December 10, 2024.
Phil L'Huillier, CEO of Scancell, expressed optimism about the clinical data from the company's lead vaccine, SCIB1, which has shown promising results in treating advanced melanoma. The funding, along with a milestone payment from Genmab (NASDAQ:GMAB), is expected to allow Scancell to progress to full clinical data for SCIB1 and iSCIB1+ and prepare for a Phase 2/3 adapted registration study.
This funding initiative follows the company's existing authorities to allot equity securities, granted at the annual general meeting on October 25, 2024. The announcement is based on a press release statement and contains inside information as defined by UK market regulations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.